Highlights from ESMO Breast 2025 by Rasha Aboelhassan
The ESMO Breast Cancer Congress 2025 taking place in Munich, Germany, on May 14-17, 2025, with an online option available through a dedicated virtual platform. It is organized by the European Society For Medical Oncology.
This focused event will bring together international experts to explore the latest innovations, discuss cutting-edge treatments, and collaborate on strategies to improve patient outcomes in breast cancer.
Attendees can expect in-depth insights into recent progress in breast cancer diagnosis, therapy, and survivorship, with a broad overview of the evolving landscape of care. The congress also offers opportunities for knowledge exchange, experience sharing, and building impactful collaborations with specialists from around the world.
Rasha Aboelhassan, Senior Oncology Consultant at Nasser Institute Hospital, shared her insights from ESMO Breast 2025 on LinkedIn:
“Great start by ESMO Breast 2025 Pfizer symposium
Experts perspective fir sequence treatment of HER2 positive breast cancer discussion of real world data with audiences international
Experts from all over the world is really great.”
((DESTINY-Breast06 (DB-06) post-hoc analysis by physician’s choice of chemotherapy (TPC): efficacy and safety of trastuzumab deruxtecan (T-DXd) vs TPC in hormone receptor–positive (HR+), HER2-low or -ultralow metastatic breast cancer (mBC) ))
thus a great success for trastuzumab deruxtecan over chemotherapy give new survival options for breast cancer patients.”
“The great debate in luminal her2 negative stage IV breast cancer:
should we use anti CD4/6 upon progression of first line anti CD 4/6 failure?
this is ( in photo ) the voting during ESMOBREAST2025.
the main answer is in resistance clones of breast cancer patients.”
Isabel Pimentel at ESMO Breast 2025
“Beautiful start for the talk:
Role of targeted therapy in mutation carries breast cancer
which patient can benefit from adjuvant PARP inhibitors?
how long should we give PARPinhibitors?
why there is PARP resistance?”
Peter Schmid at ESMO Breast 2025
“Roch symposium.
The debatable sequence of breast cancer patients with PI3K mutation
Assessment of risks / benefits and previous line of treatment is always the clue of this kind debates.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023